Savara (SVRA) Non-Current Debt (2015 - 2026)
Savara (SVRA) reported Non-Current Debt of $30.1 million for Q1 2026, up 1.84% year-over-year from $29.5 million in Q1 2025, and up 0.53% quarter-over-quarter from $29.9 million in Q4 2025.
Savara (SVRA) Non-Current Debt (2015 - 2026) Analysis & Trends
Savara (SVRA) has 12 years of Non-Current Debt data on file, last reported at $30.1 million in Q1 2026.
- Non-Current Debt for Q1 2026 came in at $30.1 million, up 1.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.1 million (up 1.84% YoY), and the FY2025 annual result was $29.9 million, up 12.35% from the prior year.
- Non-Current Debt grew to $30.1 million in Q1 2026 per SVRA's latest filing, from $29.9 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $30.1 million in Q1 2026 and troughed at $13.3 million in Q1 2022.
- A 5-year average of $26.5 million and a median of $26.4 million in 2024 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt sank 47.28% in 2022, then jumped 96.45% in 2023.
- A 5-year view of Non-Current Debt shows it stood at $26.1 million in 2022, then increased by 1.04% to $26.3 million in 2023, then climbed by 1.03% to $26.6 million in 2024, then climbed by 12.35% to $29.9 million in 2025, then advanced by 0.53% to $30.1 million in 2026.
- Business Quant data shows SVRA's Non-Current Debt at $30.1 million in Q1 2026, $29.9 million in Q4 2025, and $29.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | 30.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.07 Mn |
| Mar 31, 2026 | 30.07 Mn |
| Dec 31, 2025 | 29.91 Mn |
| Dec 31, 2025 | 29.91 Mn |
| Sep 30, 2025 | 29.78 Mn |
| Sep 30, 2025 | 29.78 Mn |
| Jun 30, 2025 | 29.65 Mn |
| Jun 30, 2025 | 29.65 Mn |
| Mar 31, 2025 | 29.52 Mn |
| Mar 31, 2025 | 29.52 Mn |
| Dec 31, 2024 | 26.62 Mn |
| Dec 31, 2024 | 26.62 Mn |
| Sep 30, 2024 | 26.55 Mn |
| Sep 30, 2024 | 26.55 Mn |
| Jun 30, 2024 | 26.48 Mn |
| Jun 30, 2024 | 26.48 Mn |
| Mar 31, 2024 | 26.42 Mn |
| Mar 31, 2024 | 26.42 Mn |
| Dec 31, 2023 | 26.35 Mn |
| Dec 31, 2023 | 26.35 Mn |